BPI-7701, a Covalent Mutant-Selective EGFR Inhibitor, Inhibits the Growth of NSCLC Lines with EGFR Activating and T790M Resistance Mutations

被引：0
|
作者：
Wilde, Victoria L. [1 ]
Zhang, Don X. [1 ]
Peng, Jirong [1 ]
Greco, Michael N. [1 ]
Green, Michael A. [1 ]
Costanzo, Michael J. [1 ]
机构：
[1] Beta Pharma Usa Inc, Res & Dev, Princeton, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
NSCLC; EGFR; T790M;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-016
引用
收藏
页码：S526 / S527
页数：2
相关论文
共 50 条
  • [21] Spectrum of Cancer Types in Kindreds with NSCLC and EGFR T790M Mutations: Results from INHERIT EGFR
    Wiesner, Georgia
    Ashworth, Renee
    Heng, Jennifer C.
    Rainville, Irene
    Mcreynolds, Katharine
    Sable-Hunt, Alicia
    Garber, Judy
    Carbone, David P.
    Oxnard, Geoffrey R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S216 - S216
  • [22] Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines
    Sato, Mami
    Fuchida, Hirokazu
    Shindo, Naoya
    Kuwata, Keiko
    Tokunaga, Keisuke
    Guo Xiao-Lin
    Inamori, Ryo
    Hosokawa, Keitaro
    Watari, Kosuke
    Shibata, Tomohiro
    Matsunaga, Naoya
    Koyanagi, Satoru
    Ohdo, Shigehiro
    Ono, Mayumi
    Ojida, Akio
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (06): : 1137 - 1144
  • [23] REVERSAL OF RESISTANCE OF EGFR TYROSINE KINASE INHIBITOR (GEFITINIB) BY EGFR T790M SPECIFIC siRNA
    Lee, C-T.
    Park, M-Y.
    Eo, E. Y.
    Lee, J. H.
    ANNALS OF ONCOLOGY, 2013, 24 : 19 - 20
  • [24] Amplification of EGFR T790M causes resistance to the irreversible EGFR inhibitor PF00299804
    Ercan, Dalia
    Zejnullahu, Kreshnik
    Xiao, Yun
    Capelletti, Marzia
    Rogers, Andrew
    Lee, Charles
    Christensen, James
    Janne, Pasi
    CANCER RESEARCH, 2009, 69
  • [25] The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
    Godin-Heymann, Nadia
    LlIkus, Lindsey
    Brannigan, Brian W.
    McDermott, Ultan
    Lamb, Jennifer
    Maheswaran, Shyamala
    Settleman, Jeffrey
    Haber, Daniel A.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) : 874 - 879
  • [26] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Kim, Youngwook
    Ko, Jeonghun
    Cui, Zhengyun
    Abolhoda, Amir
    Lee, Jeeyun
    Ahn, Jinseok
    Ou, Sai-Hong
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S421 - S421
  • [27] The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Kim, Youngwook
    Ko, Jeonghun
    Cui, ZhengYun
    Abolhoda, Amir
    Ahn, Jin Seok
    Ou, Sai-Hong
    Ahn, Myung-Ju
    Park, Keunchil
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 784 - 791
  • [28] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
    Zhang, Yidan
    Xu, Yingqi
    Xu, Jianlin
    Zhong, Hua
    Xia, Jinjing
    Zhong, Runbo
    CANCER SCIENCE, 2024,
  • [29] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [30] EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC
    Kasibhatla, Shailaja
    Li, Jie
    Tompkins, Celin
    Vaillancourt, Mei-Ting
    Anderson, Jennifer
    Pferdekamper, AnneMarie Culazzo
    Li, Chun
    Long, Oliver
    McNeill, Mathew
    Epple, Robert
    Liao, Debbie
    Murphy, Eric
    Bender, Steve
    Jia, Yong
    Lelais, Gerald
    CANCER RESEARCH, 2014, 74 (19)
12345